Clinical Pharmacokinetics of Mirtazapine
- 1.1k Downloads
Mirtazapine is the first noradrenergic and specific serotonergic antidepressant (‘NaSSA’). It is rapidly and well absorbed from the gastrointestinal tract after single and multiple oral administration, and peak plasma concentrations are reached within 2 hours. Mirtazapine binds to plasma proteins (85%) in a nonspecific and reversible way.
The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism. Mirtazapine shows linear pharmacokinetics over a dose range of 15 to 80mg. The presence of food has a minor effect on the rate, but does not affect the extent, of absorption. The pharmacokinetics of mirtazapine are dependent on gender and age: females and the elderly show higher plasma concentrations than males and young adults. The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days). Total body clearance as determined from intravenous administration to young males amounts to 31 L/h. Liver and moderate renal impairment cause an approximately 30% decrease in oral mirtazapine clearance; severe renal impairment causes a 50% decrease in clearance.
There were no clinically or statistically significant differences between poor (PM) and extensive (EM) metabolisers of debrisoquine [a cytochrome P450 (CYP) 2D6 substrate] with regard to the pharmacokinetics of the racemate. The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(−)-enantiomer (18.0±2.5h) compared with that of the (S)-(+)-enantiomer (9.9±3.1h). Genetic CYP2D6 polymorphism has different effects on the enantiomers. For the (R)-(−)-enantiomer there are no differences between EM and PM for any of the kinetic parameters; for (S)-(+)-mirtazapine the area under the concentration-time curve (AUC) is 79% larger in PM than in EM, and a corresponding longer half-life was found.
Approximately 100% of the orally administered dose is excreted via urine and faeces within 4 days. Biotransformation is mainly mediated by the CYP2D6 and CYP3A4 isoenzymes. Inhibitors of these isoenzymes, such as paroxetine and fluoxetine, cause modestly increased mirtazapine plasma concentrations (17 and 32%, respectively) without leading to clinically relevant consequences. Enzyme induction by carbamazepine causes a considerable decrease (60%) in mirtazapine plasma concentrations. Mirtazapine has little inhibitory effects on CYP isoenzymes and, therefore, the pharmacokinetics of coadministered drugs are hardly affected by mirtazapine.
Although no concentration-effect relationship could be established, it was found that with therapeutic dosages of mirtazapine (15 to 45 mg/day), plasma concentrations range on average from 5 to 100 μg/L.
- 6.Sitsen JMA, Zivkov M, Dieterle D. Wirksamkeit under Verträglichkeit von Org 3770 bei Patienten mit einer Major Depression. Psychopharmakotherapie. 1995; 2: 68–71.Google Scholar
- 8.Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatr. 1998; 59: 306–12.Google Scholar
- 12.Marttilla M, Jääskeläinen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol. 1995; 5: 441–6.Google Scholar
- 16.Montgomery SA. New developments in the treatment of depression. J Clin Psychiatry. 1999; 60 Suppl. 14: 19–5.Google Scholar
- 17.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980.Google Scholar
- 21.Colbers EPH, Boom SPA, Kleijn HJ, et al. Single-dose, fasting, open, randomized, two-way cross-over bioequivalence study on Org 3770 oral liquid versus 15 mg tablet in thirty-two healthy volunteer subjects [Study 22523, Report No. NL 0012550]. Oss: N.V. Organon, 1999. (Data on file).Google Scholar
- 24.Murdoch DL, Ashgar J, Ankier SI, et al. Influence of hepatic impairment on the pharmacokinetics of single doses of mirtazapine in elderly subjects [abstract]. Br J Clin Pharmacol. 1993; 35: 76P.Google Scholar
- 26.Paanakker JE, Tjepkema S, Timmer CJ. Pharmacokinetics of Org 3770 in young healthy male volunteers after a single oral administration of 30 and 45 mg: dose linearity testing [Study 86020, Report No. 2167]. Oss: N.V. Organon, 1988. (Data on file).Google Scholar
- 27.Timmer CJ, Paanakker JE, Mink CPA, et al. Assessment of the bioequivalence of four oral Org 3770 formulations (30mg tablet, 15mg tablet, 5mg tablet and 5mg capsule) in healthy, young, male subjects [Study 88003, Report No. 2499]. Oss: N.V. Organon, 1989. (Data on file).Google Scholar
- 28.Sitsen JMA, Voortman G, Timmer C. Pharmacokinetics of mirtazapine and lithium in healthy male subject. J Clin Psychopharmacol. In press.Google Scholar
- 29.Vrijmoed-De Vries MC, Kleijn HJ, Colbers EPH, et al. Single-dose, fasting, open, two-way cross-over bioequivalence trial on Org 3770 30 mg OraSolv® tablet versus 30 mg Org 3770 marketed tablet in 40 healthy subjects [Study 22527, Report No. NL 0016343]. Oss: N.V. Organon, 1999. (Data on file).Google Scholar
- 30.Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of Org 3770 in young healthy male volunteers after sub-chronic oral administration of escalating daily doses (15–80 mg): dose linearity testing [Study 87003, Report No. 2166]. Oss: N.V. Organon, 1988. (Data on file).Google Scholar
- 32.Peeters PAM, Brett MA, Van den Heuvel MW. A phase I, multiple dose, pharmacokinetic and safety comparison study of Org 3770 between healthy male Japanese and Caucasian volunteers [Study 22525]. Oss: N.V. Organon, 2000. (Data on file).Google Scholar
- 34.Mink L, Heftink N, Jonkman JGH, et al. Pharmacokinetics of mirtazapine in combination with amitriptyline. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4; Paris, 1.039.Google Scholar
- 35.Ebes F, Van Lookeren-Campagne AM, Hartmans HLA, et al. A phase I, single center, single-blind, placebo-controlled multiple dose study of the interaction between Org 3770 and carba-mazepine in healthy male volunteers [Study 22514, Report No. NL 0003854]. Oss: N.V. Organon, 1998. (Data on file).Google Scholar
- 36.Sitsen JMA, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. In press.Google Scholar
- 37.Van Lookeren-Campagne AM, Hartmans HLA, Ruwe FJL, et al. A phase I, single center, randomized, partially double-blind, multiple dose, three-way cross-over study of the pharmacokinetic and pharmacodynamic interaction of Org 3770 (mirtazapine) and paroxetine in healthy volunteers [Study 22511, Report No. NL 0010166]. Oss: N.V. Organon, 1998. (Data on file).Google Scholar
- 39.Midha K. Biointernational ’89. Int Pharm J 4. 1990; 3: 101–3.Google Scholar
- 40.Van der Vorstenbosch CG, Delbressine LPC. Binding of Org 3770 to human plasma proteins and human liver proteins [Report No. 2157]. Oss: N.V. Organon, 1988. (Data on file).Google Scholar
- 41.Vos RME. A pilot study on in vitro binding of Org 3770 to human erythrocytes [Report No. 3384]. Oss: N.V. Organon, 1993. (Data on file).Google Scholar
- 45.Mink CPA, Timmer CJ. A single-centre, double-blind, placebo-controlled phase I study in healthy male volunteers to assess the safety, tolerance and pharmacokinetics of intravenously administered Org 3770 [Study 22505, ReportNo. 3309]. Oss: N.V. Organon, 1993. (Data on file).Google Scholar
- 49.Hasenack HG, Otjens TCM. Enzyme induction and its reversibility in liver of rats after repeated oral administration of Org 3770 [Report no. 2124]. Oss: N.V. Organon, 1987. (Data on file).Google Scholar
- 52.Preskorn SH, Omo K, Magnus R, et al. Immediate crossover from fluoxetine to mirtazapine. Biol Psychiatry. 1997; 41: 96S.Google Scholar
- 53.Mercer AJ. The effects of ethanol alone and its interactions with other compounds on the dynamics of the saccadic eye movement system [thesis]. Cardiff: Department of Medicine, University of Wales, 1992: 202–55.Google Scholar
- 54.Mattila M, Mattila MJ, Vrijmoed-de Vries M, et al. Actions and interactions of psychotropic drugs on human performance and mood: single doses of Org 3770, amitriptyline and diazepam [Study 85148, Report No. 2468]. Oss: N.V. Organon, 1989. (Data on file).Google Scholar
- 55.Delbressine L, Dahl ML, Van den Wildenberg HM, et al. In vivo study in humans on disposition of the enantiomers and metabolites of mirtazapine [abstract] 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13–17; Vienna, 1.034.Google Scholar